Nventa Completes Evaluation Of Second Cohort In HspE7 Phase 1 Cervical Dysplasia Trial

Nventa Biopharmaceuticals Corporation (TSX:NVN) announced the completion of the safety and tolerability assessment in its second cohort of patients in a Phase 1 clinical trial of new HspE7 in patients with cervical intraepithelial neoplasia (CIN). HspE7’s safety data were normal and met the limits prescribed in the trial protocol, allowing advancement to the third cohort of patients in the study.

More: continued here

Filed under: Cervical Cancer on January 29th, 2008